• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Basic Materials·600722.SS
Share

HeBei Jinniu Chemical Industry Co.,Ltd Stocks

CN¥ 14.75Last Updated 30.09.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 1.49B

CN¥ 14.75
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HeBei Jinniu Chemical Industry Co.,Ltd, alongside its various divisions, specializes in the manufacturing and domestic distribution of methanol products across China. The methanol produced by the company finds application in a diverse range of sectors, including chemical, pharmaceutical, light manufacturing, and textile industries, among others. The firm initially operated under the name Changzhou Chemical Industry Co., Ltd, before officially adopting its current corporate identity, HeBei Jinniu Chemical Industry Co.,Ltd, in May 2008. Established in 1994, the company's principal operations are headquartered in Cangzhou, China.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.10.2026 19:00

Shares of luxury brands have fallen 25% this year. When can we expect a turnaround, and which ones should we bet on?

09.10.2026 18:49

U.S. stocks rebounded after two days of declines: Is the AI rally continuing?

09.10.2026 17:48

Data center optics are sold out for the next two years — Lumentum. Who else is seeing gains?

09.10.2026 17:26

Deeply Unpopular Stocks: Strategist Recommends Stocks to Ride Out the Sell-Off

09.10.2026 17:15

Shares of biotech company Pacira soared 44%: the maker of "Viagra" is set to acquire it

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026